Recombinant Human Thrombopoietin (rhTPO)
ITP-Thrombopoietin
Phase 3 small_molecule completed
Quick answer
Recombinant Human Thrombopoietin (rhTPO) for Immune Thrombocytopenia is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Immune Thrombocytopenia
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed